{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:13:58Z","timestamp":1788984838336,"version":"build-2803163510"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01870-3","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:12:41Z","timestamp":1785517961000},"page":"4741-4748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of 40\u00a0mg Modified-Release Doxycycline for the Treatment of Hidradenitis Suppurativa: A Single-Center Retrospective Observational Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2183-9397","authenticated-orcid":false,"given":"Gemma","family":"Cami\u00f1a-Conforto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-0534","authenticated-orcid":false,"given":"Eva","family":"Vilarrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"4","key":"1870_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344. https:\/\/doi.org\/10.1111\/jdv.12966.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1870_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899\u2013941. https:\/\/doi.org\/10.1111\/jdv.20472.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1870_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/J.AD.2019.12.006","volume":"111","author":"FJ Navarro-Trivi\u00f1o","year":"2020","unstructured":"Navarro-Trivi\u00f1o FJ, P\u00e9rez-L\u00f3pez I, Ruiz-Villaverde R. Doxycycline, an antibiotic or an anti-inflammatory agent? The most common uses in dermatology. Actas Dermosifiliogr. 2020;111(7):561\u20136. https:\/\/doi.org\/10.1016\/J.AD.2019.12.006.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"1870_CR4","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/jdv.15332","volume":"33","author":"V Bettoli","year":"2019","unstructured":"Bettoli V, Manfredini M, Massoli L, et al. Rates of antibiotic resistance\/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol. 2019;33(5):930\u20136. https:\/\/doi.org\/10.1111\/jdv.15332.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1870_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/J.JAAD.2021.11.066","volume":"86","author":"S George","year":"2022","unstructured":"George S, Muhaj FF, Nguyen CD, Tyring SK. Part I antimicrobial resistance: bacterial pathogens of dermatologic significance and implications of rising resistance. J Am Acad Dermatol. 2022;86(6):1189\u2013204. https:\/\/doi.org\/10.1016\/J.JAAD.2021.11.066.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1870_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1159\/000524762","volume":"8","author":"G Kontochristopoulos","year":"2022","unstructured":"Kontochristopoulos G, Tsiogka A, Agiasofitou E, et al. Efficacy of subantimicrobial, modified-release doxycycline compared to regular-release doxycycline for the treatment of hidradenitis suppurativa. Skin Appendage Disord. 2022;8(6):476\u201381. https:\/\/doi.org\/10.1159\/000524762.","journal-title":"Skin Appendage Disord"},{"issue":"6","key":"1870_CR7","first-page":"581","volume":"14","author":"A Moore","year":"2015","unstructured":"Moore A, Ling M, Bucko A, et al. Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40\u00a0mg versus doxycycline100\u00a0mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study. J Drugs Dermatol. 2015;14(6):581\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1870_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","volume":"85","author":"KR van Straalen","year":"2021","unstructured":"van Straalen KR, Tzellos T, Guillem P, et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study. J Am Acad Dermatol. 2021;85(2):369\u201378. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.089.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01870-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01870-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01870-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:25Z","timestamp":1788981685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01870-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1870"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01870-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gemma Cami\u00f1a-Conforto has received honoraria as a speaker for Sun Pharma, UCB and LEO Pharma. Luis Puig has perceived consultancy\/speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius Kabi, Galderma, Horizon Therapeutics, Johnson\u00a0&\u00a0Johnson, Leo-Pharma, Lilly, Novartis, Pfizer, Samsung Bioepis, Sandoz, Sanofi, STADA, Sun Pharma, and UCB. Eva Vilarrasa has received honoraria as a speaker, consultancies, research support and in participation as an investigator in clinical trials for Abbvie, Aceleryn, Almirall, Amgen, Bayer, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Citryll, Galderma, Gebro, Incyte, Isdin, Johnson\u00a0&\u00a0Johnson, Leo-Pharma, Lilly, Merck-Serono, MSD, Moonlake Inmunotherapeutics, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB. Eva Vilarrasa and Luis Puig are Editorial Board members of\n                      Dermatology and Therapy\n                      . Eva Vilarrasa and Luis Puig were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Hospital Ethics Committee (protocol code IIBSP-DOX-2024-9), which waived the requirement for informed consent to conduct the study because of the retrospective nature of data collection from routine practice records. This investigation complied with Good Clinical Practice standards and the International Council for Harmonization directives, as well as the ethical principles outlined in the Declaration of Helsinki. All data were anonymized prior to analysis.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}